一分钟看懂
这是一项关于食管鳞状细胞癌的II 期研究,登记的药物或干预包括Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab,当前状态为招募中。登记地点显示中国南京有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab · II 期
登记条件中文摘要
年龄范围:18岁至75岁
登记的基本范围为不限性别,年龄18岁至75岁;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- the First Affiliated Hospital of Nanjing Medical University · 南京
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- 1. Age ≥18 years, ≤75 years, gender is not limited;
- 2. Squamous esophageal cancer of thoracic segment confirmed by pathology;
- 3. Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal surgery, and imaging, and clinical stage cT2-4aN+ or cT3-4aN0, M0, stage II, III, or IVA (AJCC 8th edition cTNM staging);
- 4. ECOG PS score of 0-1;
- 5. No previous antitumor treatment such as radiotherapy, chemotherapy and immunotherapy;
- 6. Expected survival \> 6 months;
- 7. Adequate baseline organ function: (i) WBC ≥3×10\^9/L, ANC ≥1.5×10\^9/L, PLT ≥100×10\^9/L, Hb ≥9g/dL; (ii) Liver function: TBIL ≤2ULN, AST ≤2.5ULN, ALT ≤2.5ULN; (iii) Renal function: cCr\>40 ml/min, Cr≤1.5 ULN; (iv) Cardiac function: no cardiac disease or coronary artery disease. Cardiac function: no heart disease or coronary heart disease, patients with cardiac function grade 1-2;
- 8. Hypertensive patients applying antihypertensive drugs to control blood pressure within the normal range;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT06356688;登记信息更新于 2025-08-08;本站同步于 2026-11-21。